tetano
Editor, Senior Moderator
Curr Probl Cardiol
. 2022 Nov 7;101481.
doi: 10.1016/j.cpcardiol.2022.101481. Online ahead of print.
Nationwide Analysis of the Clinical Outcomes of Patients Admitted with COVID-19 infection with Myocarditis and Racial Disparities in Mortality
Harmon R Cannon[SUP] 1 [/SUP], Aniesh Bobba[SUP] 2 [/SUP], Rahul Shekhar[SUP] 1 [/SUP], Karthik Gangu[SUP] 3 [/SUP], Shazib Sagheer[SUP] 4 [/SUP], Prabal Chourasia[SUP] 5 [/SUP], Ishan Garg[SUP] 1 [/SUP], Hina Shuja[SUP] 6 [/SUP], Najam Wasty[SUP] 7 [/SUP], Abu Baker Sheikh[SUP] 8 [/SUP]
Affiliations
Abstract
Coronavirus-19 (COVID-19), while primarily a respiratory virus, affects multiple organ systems, including the cardiovascular system. The relationship between COVID-19 and Myocarditis has been well established, but there are limited large-scale studies evaluating outcome of COVID-19 related Myocarditis. Using National Inpatient Sample (NIS) database, we compared patients with Myocarditis with and without COVID-19 infection. The primary outcome was in-hospital mortality. Secondary outcomes were acute kidney injury requiring hemodialysis, vasopressor use, mechanical ventilation, cardiogenic shock, mechanical circulatory support, sudden cardiac arrest, and length of hospitalization. A total of 17,970 patients were included in study; Myocarditis without COVID (n=11,515, 64%) and Myocarditis with COVID-19 (n= 6,455, 36%). Patients with COVID-19 and Myocarditis had higher in-hospital mortality compared to those with Myocarditis alone (30.7% vs. 6.4%, odds ratio 4.8, 95% CI 3.7-6.3, p < 0.001). That cohort also had significantly higher rates of vasopressor use, mechanical ventilation, sudden cardiac arrest, and acute kidney injury requiring hemodialysis. Given the poor outcome seen in COVID-19 related Myocarditis cohort, further work is needed for development of directed therapies for COVID-19-related Myocarditis.
Keywords: COVID-19; Incidence; Mortality; Myocarditis.
. 2022 Nov 7;101481.
doi: 10.1016/j.cpcardiol.2022.101481. Online ahead of print.
Nationwide Analysis of the Clinical Outcomes of Patients Admitted with COVID-19 infection with Myocarditis and Racial Disparities in Mortality
Harmon R Cannon[SUP] 1 [/SUP], Aniesh Bobba[SUP] 2 [/SUP], Rahul Shekhar[SUP] 1 [/SUP], Karthik Gangu[SUP] 3 [/SUP], Shazib Sagheer[SUP] 4 [/SUP], Prabal Chourasia[SUP] 5 [/SUP], Ishan Garg[SUP] 1 [/SUP], Hina Shuja[SUP] 6 [/SUP], Najam Wasty[SUP] 7 [/SUP], Abu Baker Sheikh[SUP] 8 [/SUP]
Affiliations
- PMID: 36356700
- DOI: 10.1016/j.cpcardiol.2022.101481
Abstract
Coronavirus-19 (COVID-19), while primarily a respiratory virus, affects multiple organ systems, including the cardiovascular system. The relationship between COVID-19 and Myocarditis has been well established, but there are limited large-scale studies evaluating outcome of COVID-19 related Myocarditis. Using National Inpatient Sample (NIS) database, we compared patients with Myocarditis with and without COVID-19 infection. The primary outcome was in-hospital mortality. Secondary outcomes were acute kidney injury requiring hemodialysis, vasopressor use, mechanical ventilation, cardiogenic shock, mechanical circulatory support, sudden cardiac arrest, and length of hospitalization. A total of 17,970 patients were included in study; Myocarditis without COVID (n=11,515, 64%) and Myocarditis with COVID-19 (n= 6,455, 36%). Patients with COVID-19 and Myocarditis had higher in-hospital mortality compared to those with Myocarditis alone (30.7% vs. 6.4%, odds ratio 4.8, 95% CI 3.7-6.3, p < 0.001). That cohort also had significantly higher rates of vasopressor use, mechanical ventilation, sudden cardiac arrest, and acute kidney injury requiring hemodialysis. Given the poor outcome seen in COVID-19 related Myocarditis cohort, further work is needed for development of directed therapies for COVID-19-related Myocarditis.
Keywords: COVID-19; Incidence; Mortality; Myocarditis.